Substance / Medication

Anagrelide

SNOMED 372561005 UMLS C0051809

Overview

Active Ingredient

anagrelide

RxNorm CUI

596724

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Thrombocytosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

NCT00202644Phase 4Completed150 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.

Abreu Lopez Barbara, Arvelaez Pascucci Joanne, Ramzy Safiya Mohamed et al. · Int J Hematol · 2025

PMID: 40057935Meta-Analysis

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

Petrides Petro E, Schoergenhofer Christian, Widmann Rudolf et al. · Clin Pharmacol Drug Dev · 2018

PMID: 28301098RCTFull text (PMC)

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Petrides Petro E, Gisslinger Heinz, Steurer Michael et al. · Clin Ther · 2009

PMID: 19302911RCT

Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.

Gotic Mirjana, Egyed Miklos, Gercheva Liana et al. · Cardiovasc Toxicol · 2021

PMID: 33123978TrialFull text (PMC)

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Gisslinger Heinz, Buxhofer-Ausch Veronika, Hodisch Juri et al. · Br J Haematol · 2019

PMID: 30919941TrialFull text (PMC)

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Kanakura Yuzuru, Shirasugi Yukari, Yamaguchi Hiroki et al. · Int J Hematol · 2018

PMID: 30121892Trial

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Birgegård Gunnar, Besses Carlos, Griesshammer Martin et al. · Haematologica · 2018

PMID: 29079600TrialFull text (PMC)

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Gugliotta Luigi, Besses Carlos, Griesshammer Martin et al. · Haematologica · 2014

PMID: 24334294TrialFull text (PMC)

Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.

Kanakura Yuzuru, Miyakawa Yoshitaka, Wilde Paul et al. · Int J Hematol · 2014

PMID: 25160063Trial

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.

Rey Jérôme, Viallard Jean-François, Keddad Karim et al. · Eur J Haematol · 2014

PMID: 24118452TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Anagrelide (substance)
SNOMED CT: 372561005
UMLS CUI: C0051809
RxNorm CUI: 596724

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.